Status:
TERMINATED
Therapeutic Effect of Sodium Intake Reduction in Treatment Resistant Hypertension
Lead Sponsor:
DongGuk University
Conditions:
Sodium Intake
Resistant Hypertension
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
The aim of this study was to evaluate the therapeutic effect of sodium intake reduction by education in patients with resistant hypertension. The study was designed to maximize the compliance to anti...
Detailed Description
The study consists of 3 phases. The first phase is to exclude pseudo-resistant hypertension by improving compliance to antihypertensive medications. Patients should visit with a prescribed antihyperte...
Eligibility Criteria
Inclusion
- individuals who agreed to participate in the study and submitted written informed consent
- individuals aged 20 or more years
- Hypertensive patients whose blood pressure is not controlled normally while taking three or more antihypertensive agents including diuretics
- Diuretics should be Hydrochlorothiazide or Indapamide
Exclusion
- Systolic blood pressure ≥ 220 mmHg
- Chronic kidney disease: estimated Glomerular filtration rate by Modification of Diet in Renal Disease formula ≤ 30 mL/min
- Hyperkalemia (\>5.5 mmol/L) or hypokalemia (\<3.5 mmol/L)
- Hyponatremia (\<135 mmol/L)
- Major cardiovascular events (MI, unstable angina, coronary revascularization, stroke) within 6 month of screening
- Retinal bleeding within 3 months
- Heart failure stage 3 or 4
- Severe liver disease
- Pregnancy or women in the fertile age not using efficient contraceptive methods
- Alcoholism
- Renovascular disease
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2020
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT03424317
Start Date
January 1 2018
End Date
August 31 2020
Last Update
July 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dongguk University Ilsan Hospital
Goyang-si, Gyeonggi-do, South Korea, 410-773